Rzeszow

• Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting
  2023-509179-18-00 1 2019-08-13 Castration Resistant Prostate Cancer (CRPC)
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 5 2019-08-01 Lymphoblastic lymphoma
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• A Phase 2 Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Pediatric Sub … Ended recruitment
  2022-501349-64-00 4 2026-01-12 Symptomatic nonerosive GERD in paediatric subjects aged 2 to 11 years
• A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 Years of Age With Severe Alopecia Areata Ended recruitment
  2024-515438-33-00 5 2026-01-12 Alopecia areata
• A study to find if tibulizumab works and how safe it is in participants with systemic sclerosis Ended recruitment
  2024-519335-42-01 4 2025-12-22 Systemic Sclerosis
• A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants with Severe Asthma Ended recruitment
  2024-519469-23-00 4 2025-10-20 Severe Asthma
• Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended recruitment
  2025-520488-42-00 4 2025-09-17 Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
• A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended recruitment
  2025-520521-21-00 5 2025-09-02 Hyperlipidemia
• A Phase 2b Study to Assess IMVT-1402 in Participants with Cutaneous Lupus Erythematosus Ended recruitment
  2024-516745-39-00 4 2025-07-11 Cutaneous lupus erythematosus
• Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis. Ended recruitment
  2024-515672-12-00 5 2025-05-27 Moderate to Severe Genital Psoriasis
• A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Atopic Dermatitis Ended recruitment
  2024-515494-95-00 4 2025-05-26 Moderate to Severe Atopic Dermatitis (AD)
• A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P55 with Cosentyx in Patients with Moderat … Ended recruitment
  2024-513348-27-00 5 2025-05-09 Plaque psoriasis
• A research study comparing how well different doses of the medicine NNC0519-0130 can reduce kidney damage in people living with chronic kidn … Ended recruitment
  2024-510846-15-00 4 2025-04-14 Chronic Kidney Disease, with or without Type 2 diabetes, Obesity
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513210-36-00 5 2025-04-04 Chronic Spontaneous Urticaria
• Role of Pancreatic Enzyme Replacement Therapy (PERT) (Creon®) in Pancreatic Exocrine Insufficiency (PEI) due to gastrectomy. Ended recruitment
  2023-507837-18-00 6 2025-03-06 Male and female patients aged ≥ 18 to ≤ 80 after total gastrectomy.
• A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Participants with Dry Age-Related Macular Degeneration … Ended recruitment
  2024-515022-88-00 5 2025-03-03 Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (GA
• STEP TEENS Weight Maintenance: A research study on how well semaglutide helps teenagers with excess body weight to lose weight and maintain … Ended recruitment
  2023-508055-40-00 6 2025-02-18 Obesity
• Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 2 (STOP-PN2) Ended recruitment
  2024-511881-35-00 5 2024-12-17 Prurigo Nodularis
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata Patients (Rezolve AA) Ended recruitment
  2023-509981-39-00 4 2024-11-20 Alopecia Areata
• A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended recruitment
  2023-510341-19-00 5 2024-11-14 acne vulgaris
• Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients Ended recruitment
  2023-504040-34-01 5 2024-11-12 Crohn’s Disease
• A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil … Ended recruitment
  2023-510342-24-00 5 2024-11-11 Acne vulgaris

Showing 145–168 of 324 trials